Cytek Biosciences (CTKB) 44th Annual J.P. Morgan Healthcare Conference summary

Company achievements and market position

• Recognized as a leading cell analysis company, named among the fastest growing by TIME and awarded for innovation and drug discovery solutions in 2025.

• Shipped over 3,400 instruments to more than 2,000 unique customers in 70+ countries since 2016.

• 2024 and preliminary 2025 revenue reached $201 million, with $262 million in cash and marketable securities as of September 2025.

• Revenue distribution: 50% U.S., 26% EMEA, 24% APAC/ROW; 59% from biotech/pharma/distribution, 41% from academia/government.

• Market opportunity projected to grow from $5.1 billion in 2025 to $9.2 billion by 2032 at 8.8% CAGR.

Business pillars and technology innovation

• Five business pillars: instruments, applications, bioinformatics, clinical, and services.

• Continuous investment in instrument performance, intelligence, and data harmonization.

• Cytek Cloud user base grew 40% in 2025, surpassing 22,600 users and supporting automated panel design.

• Clinical instruments approved in China and Europe, with improved sensitivity for MRD applications.

• AI-driven data analysis and harmonization enhance clinical and research applications.

Product portfolio and growth drivers

• Broad portfolio includes conventional, full spectral, and imaging-based flow cytometry tools.

• Aurora Evo, launched in 2024, offers high throughput and advanced features, driving replacement cycles.

• Reagent business expanded post-2021 acquisition of Tonbo; 2024 reagent revenue grew over 20%, and Q3 2025 reagent revenue grew ~21%.

• Acquired Luminex assets in 2023 to enter imaging space and formed partnerships with Bio-Rad and Luminex.

• Service and reagent revenue, plus APAC instrument sales, comprise 50% of business and grew double digits in 2024; recurring revenue base continues to expand.